WASHINGTON — Pfizer CEO Albert Bourla praised the new agreement with President Donald Trump’s administration, emphasizing that the deal will directly benefit the American people.

“The big winner of this deal clearly will be the American patient — there’s no doubt about it,” Bourla said. “They are the ones that will see significant impact in their ability to buy medicines. We are ready to unleash our investment portfolio in this country.”

The agreement, announced earlier this week, ensures that Pfizer will offer its most popular prescription drugs at discounts of 50% to 100% and commit all new medications to Most Favored Nation (MFN) pricing in the U.S. Analysts note that this could not only make lifesaving treatments more affordable but also attract further pharmaceutical investments in American healthcare infrastructure.

By tying Pfizer’s future growth to affordability and access, the deal is being hailed as a milestone in Trump’s ongoing push to reduce prescription drug costs while strengthening U.S. healthcare.